Catecholaminergic Polymorphic Ventricular Tachycardia
11
5
5
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
A Phase 2 Study of CRD-4730 in CPVT
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Baby Detect : Genomic Newborn Screening
Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations
Clinical Cohort Study - TRUST
Physical Activity in Children With Inherited Cardiac Diseases
Long Term Monitoring for Risk of Sudden Death
Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia